Small molecule · Inhibitor of calcineurin (PPP3CA) · developed by Aurinia
Voclosporin is a calcineurin inhibitor immunosuppressant that suppresses lymphocyte activation by inhibiting calcineurin-mediated dephosphorylation of NFATc, reducing T-cell proliferation and cytokine production. It also stabilizes podocyte cytoskeleton integrity in the kidney.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07611214 | Phase 4 | Lupus Nephritis | Recruiting | AUPH |
| NCT05288855 | Phase 3 | Adolescent Lupus Nephritis | Terminated | AUPH |
| NCT04147650 | Phase 2/3 | Dry Eye Syndrome | Completed | AUPH |
| NCT03597139 | Phase 2 | Dry Eye | Completed | AUPH |
| NCT02141672 | Phase 2 | Lupus Nephritis | Completed | AUPH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adolescent Lupus NephritisDry EyeDry Eye SyndromeKeratoconjunctivitis SiccaLupus NephritisPediatric Lupus Nephritis
Updated Oct 3, 2026. Something wrong or missing? Report it on the AUPH page.
See AUPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AUPH catalysts and pipeline →